anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ARM 1: Meals only. Participants randomized to receive "meals only" will receive 14 frozen meals, delivered 1x/week, for 3-months. Participants will be provided with a menu of 40 meal options and instructions for how to select their meals and change weekly meal selections (if desired). Participants in this arm will also receive nutrition education and fall prevention handouts. Nutrition education handouts will indicate which of LifeCare Alliance's meals are considered to be "heart healthy" as well as "diabetic-friendly." Participants will have the autonomy to select their own meals according to their preferences and their ability to self-manage their own health conditions (e.g., diabetes, cardiovascular disease). Fall prevention education handouts will provide guidance on how to reduce fall risk at home and modify the home environment to eliminate fall hazards.
The invention relates to a water-soluble liquid anti-dandruff shampoo used by people, the formula of which is that: A. 0.5-2 percent aloe extract, B. 0.5-2 percent Korean ginseng extract, C. 0.2-2 percent panthenol, D. 0.03-0.08 percent hyaluronic acid, E. 0.2-2 percent climbazole, F. 0.2-2 percent pyrithione ethanolamine salt, G. 0.01-2 percent vitamin E, H. 0.1-1 percent mint, I. 3-40 percent ethanol and J. 20-80 percent o water. The preparation method is that: 1. appropriate amount of water is added into A, C, D and F provided to acquire a X solution; 2. ethanol is added into B, E, G and H and a Y solution is acquired; 3. the X solution is added into the Y solution gradually and mixed, thus obtaining the anti-dandruff shampoo. The invention solves the defects of inconvenient usage of the prior anti-dandruff shampoo and bad anti-dandruff effect. When being used, the invention is directly applied to scalp and is anti-dandruff efficient. The invention also has the advantages of convenience and rapidness, good and long-lasting anti-dandruff effect particularly, thus achieving the goal of convenient and rapid anti-dandruff with good effect.
Reactive oxygen species (ROS) are considered a primary source of damage during ischemic stroke. However, the precise timing of ROS production (during hypoxia or reperfusion) remains unclear. Cellular 3D spheroids are often proposed as an optimal alternative to both 2D cell cultures and animal models in modeling disease conditions. Here we report live imaging of hydrogen peroxide dynamics during the acute phase of hypoxia and reperfusion in human iPSC-derived neural spheroids, stably expressing fluorescent biosensor HyPer7. Contrary to previous reports, we did not observe a hydrogen peroxide production burst neither during hypoxia nor in course of reperfusion. Our data suggest either lack of oxidative stress during ischemia-reperfusion in spheroids or existence of different mechanisms of oxidative damage.
Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
Heat-killed, terminally sterilized saline suspensions of Propionibacterum acnes, Propionibacterium avidum, Propionibacterium lymphophylum, Propionibacterium granulosum, Cornynebacterium parvum, and Arachnia propionica are effective in treating viral infections of the respiratory tract in humans, and to induce the regression of dermal tumors and warts in humans. The potency of a saline suspension of heat-killed, terminally sterilized saline suspension of Propionibacterium acnes (P. acnes) was demonstrated through a laboratory animal challenge model. The P. acnes product is administered orally for the purpose of preventing or treating viral infections of the respiratory tract in man. The P. acnes preparation is intralesionally administered into dermal tumors, warts such as plantar warts, or other warts in people caused by the human papilloma virus, to cause regression of such dermal tumors and warts.  The subcutaneous route of administration of the P. acnes product causes a systemic reaction that causes long-term warts to completely regress.  Anesthetics such a Lidocaine may be added to the P. acnes product to prevent pain upon injection of this immune modulating preparation, while retaining the potency of the P. acnes product. Dose ranges have been established for the oral administration of the P. acnes product to treat viral infections, and for the subcutaneous and intralesional administration of the P. acnes product to treat dermal tumors and warts.
PRIMARY OBJECTIVES: I. Study fludeoxyglucose \[18F\] 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil-clevudine (FMAU) (fluorine F 18-clevudine ) in 10 patients with known breast cancer to obtain data on safety, circulating metabolite, tumor imaging feasibility, and radiation dosimetry. II. Assess the potential utility of FMAU-PET in the imaging evaluation of chemotherapeutic response in 15 patients with breast cancer. OUTLINE: Patients receive fluorine F18-clevudine intravenously (IV) over 1 minute and then undergo PET/CT scan at baseline. Patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment. After completion of study treatment, patients are followed up at 24 hours.
Crohn's disease (CD) is a lifelong disease that may present during childhood in 20 - 25% of patients. There seems to be a worldwide trend towards increasing incidence rates of CD, especially in children. Patients with CD suffer from diarrhea, abdominal pain, nausea, malaise, and chronic malnutrition, in children often accompanied by growth failure and pubertal delay. CD is characterized by a transmural, granulomatous inflammation, involving any part of the gastrointestinal tract in a discontinuous manner.

Increased concentrations of tumor necrosis factor-α (TNFα) are found in the mucosa of CD patients , suggesting that TNF-α plays a pivotal role in the cytokine cascade of the inflammatory process. This key role of TNF-α has led to the development of biologic therapy based on the administration of monoclonal antibodies which bind and inactivate TNF-α. Infliximab (IFX, Remicade®) is a chimeric monoclonal antibody (75% human, 25% murine), while adalimumab (ADA, Humira®) is a fully human monoclonal antibody. Both antibodies bind with high affinity and specificity to soluble and membrane-bound TNF-α.

Anti-TNF drugs have become an important treatment strategy for CD patients who do not respond to or are intolerant of treatment with immunosuppressants (azathioprine, methotrexate) and corticosteroids. Anti-TNF induction therapy can induce complete clinical remission within weeks, often accompanied by mucosal healing. Interestingly, response to initial anti-TNF treatment is higher in pediatric CD patients (about 80%) than in adult CD patients (about 60%). Anti-TNF drugs do not cure CD: after their impressive initial effects, repeated infusions every 8 weeks or repeated subcutaneous injections every 2 weeks are necessary, while there is great concern about the long-term risks (infections, auto-immune disease, malignancy). Anti-TNF treatment is also increasingly used in ulcerative colitis, and has been shown to induce remission in active disease. For UC, the comparison between the efficacy in children versus adults is more difficult to report as studies in children are scarce. There are likely multiple host factors that influence the inter-individual variation in initial treatment response, such as disease phenotype, immune phenotype, and genetic background.
PURPOSE: This study aimed to report the safety and feasibility of single-incision robotic totally extra-peritoneal repair (TEP) with the da Vinci Xi platform.
METHODS: We prospectively included patients with unilateral inguinal hernia who underwent elective single-incision robotic TEP between August 10, 2021 and December 12, 2022. The primary outcome was the determination of postoperative complications, and secondary outcomes were quality of life and recurrence rate.
RESULTS: Twenty patients were included in this study. The median age of patients was 60 (interquartile range [IQR], 44.8-62) years, and most were male (90%). Eighteen patients had an indirect hernia. The median total operative time was 70 (IQR, 60.5-82.0) min, the median docking time was 5 (IQR, 3.3-6.0) min, and the median console time was 42 (IQR, 30.3-49.8) min. No postoperative complications occurred within six months postoperatively. We observed an upward trend in quality of life, which was low preoperatively, with improvement noted one month postoperatively. During the six-month follow-up period, there were no cases of recurrence.
CONCLUSION: For uncomplicated inguinal hernias, single-incision robotic TEP using the da Vinci Xi platform can be selectively and safely attempted.
A method and agents are disclosed for raising the tolerance of animal tissue to antibiotic compounds that induce oxidant stress. The method comprises administering one or more nontoxic redox compounds to the locus of administration of the antibiotic in an amount sufficient to diminish the production of the potentially toxic oxidants. The redox compounds may be administered by various parenteral techniques. The agents comprise redox compounds and include redox dyes such as those of the thiazine group. Of this group methylene blue is preferred. A method for treating cancer in animals is also disclosed.
Metastasis accounts for the majority of cases of cancer recurrence and death in patients with advanced non-small cell lung cancer (NSCLC). Farnesoid X Receptor (FXR) is a bile acid nuclear receptor that was recently found to be upregulated in NSCLC tissues. However, whether and how FXR regulates NSCLC metastasis remains unclear. In the present study, it was found that FXR promoted the migration, invasion, and angiogenic ability of NSCLC cells in vitro, and increased NSCLC metastasis in a mouse model in vivo. Mechanistic investigation demonstrated that FXR specifically bound to the promoters of IL-6ST and IL-6 genes to upregulate their transcription, thereby leading to activation of the Jak2/STAT3 signaling pathway, which facilitated tumor migration, invasion, and angiogenesis in NSCLC. Notably, Z-guggulsterone, a natural FXR inhibitor, significantly reduced FXRhigh NSCLC metastasis, and decreased the expression of FXR, IL-6, IL-6ST, and p-STAT3 in the mouse model. Clinical analysis verified that FXR was positively correlated with IL-6, IL-6ST and p-STAT3 expression in NSCLC patients, and was indicative of a poor prognosis. Collectively, these results highlight a novel FXR-induced IL-6/IL-6ST/Jak2/STAT3 axis in NSCLC metastasis, and a promising therapeutic means for treating FXRhigh metastatic NSCLC.
Intervention group 1 (IG1) will carry out personalised and adapted computerised cognitive stimulation (CE) through the stimulus platform; 30 minutes/day, 5 days/week, 8 weeks; 40 sessions. The following will be worked on: memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration and executive functions.
High blood pressure in the portal vein, portal hypertension (PH), is the final common pathway in liver cirrhosis regardless of aetiology. Complications from PH are the major cause of morbidity and mortality in these patients. Current drug therapy to reduce portal pressure is mainly limited to β-adrenergic receptor blockade but approximately 40% of patients do not respond. Our aim was to use microarray to measure the expression of ∼20,800 genes in portal vein from patients with PH undergoing transplantation for liver cirrhosis (PH, n=12) versus healthy vessels (control, n=9) to identify potential drug targets to improve therapy. Expression of 9,964 genes above background was detected in portal vein samples. Comparing PH veins versus control (adjusted P-value < 0.05, fold change > 1.5) identified 548 up-regulated genes and 1,996 down-regulated genes. The 2,544 differentially expressed genes were subjected to pathway analysis. We identified 49 significantly enriched pathways. The endothelin pathway was ranked the tenth most significant, the only vasoconstrictive pathway to be identified. ET-1 gene (EDN1) was significantly up-regulated, consistent with elevated levels of ET-1 peptide previously measured in PH and cirrhosis. ETA receptor gene (EDNRA) was significantly down-regulated, consistent with an adaptive response to increased peptide levels in the portal vein but there was no change in the ETB gene (EDNRB). The results provide further support for evaluating the efficacy of ETA receptor antagonists as a potential therapy in addition to β-blockers in patients with PH and cirrhosis.
The present invention provides a method for increasing the proportion of a central memory T cell (Tcm) subset in a CAR-T cell product. The method includes adding an artificial antigenic epitope in a CAR, and activating a CAR-T by the artificial antigenic epitope, wherein the artificial antigenic epitope does not exist in other domains or segments of the CAR. The present invention further provides a method for preparing a CAR-T cell. The preparation method includes: (1) introducing the CAR into a T cell; and (2) culturing the CAR-introduced T cell, and performing specific activation in the culture process. The preparation method can not only increase the proportion of CAR-positive T cells in the product, but also can achieve specific in vitro amplification of the Tcm subset in the CAR-positive T cells, and significantly increases the proportion of Tcm in a final product. Clinical trials show that the CAR-T cells prepared by the present invention have significantly better amplification capacity in vivo than the prior art, and have better clinical safety and effectiveness
This is a prospective, longitudinal, multi-center, observational study designed to evaluate the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) in ambulatory and non-ambulatory adult patients with SMA. Subjects with SMA II/III that are 18 years to 70 years of age who are planning to initiate treatment with SPINRAZA® (nusinersen) as part of their clinical care plan will be enrolled in this study. This study does not provide SPINRAZA® (nusinersen) or cover costs associated with standard clinical care.These patients will be treated by their respective physicians according to standard clinical practice. Study visits, some of which including standardized assessments of strength and function, will occur at baseline, day 15 after treatment initiation, day 30, day 60, and then 4-month intervals through month 30.
FIELD: pharmacy, medicine, molecular biology, biotechnology. SUBSTANCE: invention is related to method and composition useful for patients suffering with different disturbances and showing anomal levels of one or more components activity of which is regulated or acts on activity of one or more receptors of inorganic ions. Also, compounds useful in these methods and compositions were given. Method involves the administration to patient therapeutically effective amount of molecule showing activity with regard to one or more receptors of inorganic ions as agent or antagonist. Preferably, molecule must act as selective against or antagonist on the Ca-receptor of one or more (but not all) cells taken in group. Group consists of parathyroid cells, osseous osteoclasts, periglomerular renal cells, proximal tubular renal cells, peripheral tubular renal cells, thick ascending branch of Henle loop cells and/or ducts collecting, keratinocyte in epidermis, parafollicular cell in thyroid (C-cells), intestinal cells, trophoblast in placenta, platelet, smooth muscle vessel cells, atrium cells, cells producing gastrin and glucagon, renal mesangial cell and mammary cells. EFFECT: increased effectiveness of combinations proposed.
The invention provides an application of hawthorn seed acetylated xylo-oligosaccharide in preparing an anti-tumor product. In vitro experiments show that the hawthorn seed acetylated xylo-oligosaccharide has remarkable growth inhibition effect on human colon cancer cells, liver cancer cells and non-small cell lung cancer cells in logarithmic growth phase. The in vivo anti-tumor effect of the hawthorn seed acetylated xylooligosaccharide is evaluated by using a tumor-bearing mouse model, and the hawthorn seed acetylated xylooligosaccharide has good inhibition effect on the tumor growth of mice with tumor bearing intestinal cancer of HCT116 cell line and has no toxic or side effect on liver and kidney. The hawthorn seed acetylated xylooligosaccharide regulates a PI3K-Akt signal pathway, promotes the expression of Bax, and leads to the activation and apoptosis of Caspase-3. The acetic acid and propionic acid levels in the feces after the high-dose haw seed acetylated xylo-oligosaccharide intervention are increased by 109% and 290% respectively. The invention provides a new choice for treating or preventing tumors.
This article examines the risk of infective endocarditis (IE) linked to various bacterial species causing bacteremia. While the European Society of Cardiology (ESC) and the American Heart Association (AHA) guidelines do not specify the diagnostic workup to perform based on bacterial species, certain bacteria are acknowledged to pose a higher IE risk. Community-acquired bacteremia has a higher IE risk than nosocomial bacteremia. Implantable electronic cardiovascular devices (IECD) and a history of IE or valve surgery also increase this risk. Several risk stratification systems (RSS) have been developed to guide clinicians on the necessity of echocardiography in patients with Gram-positive bacteremia, particularly S. aureus, streptococci, and enterococci. An evaluation algorithm based on these RSS is proposed to assist clinical investigations.
Risk Summary

Radioactive iodine products cross the placenta and can permanently impair fetal thyroid function. Administration of an appropriate thyroid blocking agent is recommended before use of AdreView in a pregnant woman to protect the woman and fetus from accumulation of I 123 [see Dosage and Administration (2.2) ].

There are no available data on AdreView use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with iobenguane I 123. All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. Advise pregnant women of the potential risks of fetal exposure to radiation doses with administration of AdreView. 

AdreView contains 10.3 mg/mL of benzyl alcohol. Because benzyl alcohol is rapidly metabolized by a pregnant woman, benzyl alcohol exposure in the fetus is unlikely. However, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4)].

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
An example system for monitoring an occupant of a room includes an enclosure, a speaker plate, a speaker, an infrared illuminator, a camera, and a power-over-Ethernet (PoE) splitter. The enclosure is mountable within an interior surface of the room. The speaker plate is removably positionable within the enclosure, and includes a speaker opening and an illuminator opening. The speaker is positioned within the speaker opening and mounted to the speaker plate. The infrared illuminator is positioned within the illuminator opening and mounted to the speaker plate. The PoE splitter is configured to: receive power and data over a first Ethernet cable, provide power to the speaker, the infrared illuminator, and the camera; and output the data to the camera over a second Ethernet cable. The camera is configured to send an audio signal to the speaker over an audio cable.
Central venous catheters are used for fluid infusion, nutrition, blood transfusion, hemodynamic monitorization in both intensive care unit and operating room. The superior vena cava and right atrium (SVC-RA) junction is considered the optimal position for central venous catheter tip. Carina corresponds to the SVC-RA junction on chest radiograph. Catheter tips, 1 cm above and 1 cm below the carina are considered as the correct position. 18-70 years old patients will be enrolled for the study. Central venous catheters will be inserted via internal jugular vein or subclavian vein using patient's height formula by Seldinger technique. Postprocedural (within 6 hours) chest radiograph will be used to evaluate the correct tip position from the Picture Archiving and Communication System. This formula was described by Peres. If the tip of the catheter is below the carina more than 1 cm, it will be pulled back for repositioning. If the tip of the catheter is above the carina more than 1 cm, another catheter will be inserted. The formula is height (cm)/10 for right internal jugular vein, height(cm)/10-2 for right subclavian vein, height(cm)/10+4 for left internal jugular vein and height(cm)/10+2 for left subclavian vein. Number of the correct and incorrect position of central venous catheter tips will be noted.

The investigators aim to evaluate the reliability and efficiency of Peres' formula for the correct tip position.
This clinical trial is for men with progressive metastatic castration-resistant prostate cancer (mCRPC). The primary objectives of the study are to determine the optimal dose of 225Ac-J591 when combined with pembrolizumab (phase I) and then to assess whether the combination of 225Ac-J591, pembrolizumab, and androgen receptor pathway inhibitor (ARPI) is more effective against prostate cancer than pembrolizumab and ARPI alone. 225Ac-J591 is a radionuclide conjugate involving Actinium-225 linked to J591, an antibody that recognizes prostate-specific membrane antigen (PSMA) on the surface of cancer cells; 225Ac-J591 is able to deliver powerful radiation to cancer cells. Pembrolizumab is a drug that strengthens the body's immune response to cancer cells. In the phase I portion of the study, two cohorts of up to 6 patients each will receive combined therapy: ARPI (standard dosing schedule), pembrolizumab (400 mg every 6 weeks), 225Ac-J591 (single dose, either 65 or 90 KBq/kg). Following a minimum of 12 weeks of safety follow-up, the study team will determine which 225Ac-J591 dose is better. In the phase II portion, patients will be randomized to pembrolizumab + ARPI with or without 225Ac-J591. The primary endpoint for phase II will be response - a composite of PSA, circulating tumor cell (CTC) count, and imaging changes. Patients who achieve at least one of the criteria will be considered responders. Imaging (CT scan, bone scan) will occur every 12 weeks. Additionally, participants will undergo 68Ga-PSMA-11 PET/CT scan prior to therapy and at 12 weeks. Patients are able to receive pembrolizumab every 6 weeks for maximum 18 cycles (approximately 2 years).